NASDAQ: GERN
Geron Corporation
Healthcare · Biotechnology
After hours: $1.26(0%) · as of 7:26 PM ET
Market Cap
$808.32M
52w High
$2.01
52w Low
$1.04
P/E
-12.12
Volume
19.57M
Outstanding Shares
641.52M
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock fell 18.71% over the last year. Revenue grew 68.64% over the trailing twelve months. Operating margin moved from -115.49% to -19.05%. Free cash flow grew 38.21% over the trailing twelve months.
What the market seems to be pricing
Visible fundamentals weakened far less than the stock price. The market appears to be discounting durability, risk, or trust rather than just the latest reported numbers.
What would invalidate this read
This read changes if operating margin (currently -19.05%) continues to decline, or if revenue growth turns negative. The bull case requires the business to hold its current trajectory.
Company profile
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers.
Valuation
Stock splits
Every 500 shares became 529
Profitability & growth
Analyst consensus
17
Buy
5
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Aug 5, 2026
Q3 FY26 · EPS est -$0.01 · Revenue est $55.21M
View